Ardelyx, Inc. – NASDAQ:ARDX

Add to watchlist

$5.84

+0.62

+12.09%

Market closed

Open in 2 days

-11.54%

month

-11.54%

quarter

-20.09%

year

Market Cap	1.10B
Enterprise value	825.49M

P/E	-11.79
EV/Sales	15.82
EV/EBITDA	-13.53
Price/Sales	16.97
Price/Book	9.00
PEG ratio	-0.16
EPS	-0.27

Revenue	159.11M
EBITDA	-56.58M
Income	-65.81M
Revenue Q/Q	304.81%
Revenue Y/Y	152.31%

Profit margin	-128.85%
Oper. margin	-122.24%
Gross margin	92.11%
EBIT margin	-122.24%
EBITDA margin	-35.56%

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Ardelyx, Inc. (NASDAQ:ARDX): Profit margin
Jun 2023	22.33M	-17.12M	-76.66%
Sep 2023	56.39M	6.62M	11.76%
Dec 2023	34.36M	-28.80M	-83.82%
Mar 2024	46.02M	-26.51M	-57.62%

Ardelyx Financials Estimate

Q Y

Ardelyx, Inc. (NASDAQ:ARDX): Analyst Estimates
Mar 2024	46.02M	-26.51M	-57.62%
Sep 2025	99.75M	7.74M	7.76%
Oct 2025	105.42M	11.09M	10.52%
Dec 2025	118.75M	20.85M	17.56%

Analysts Price target
Financials & Ratios estimates

Ardelyx, Inc. (NASDAQ:ARDX): Debt to assets
Jun 2023	211203000	88.04M	41.69%
Sep 2023	289379000	98.21M	33.94%
Dec 2023	297579000	130.76M	43.94%
Mar 2024	342382000	191.49M	55.93%

Ardelyx, Inc. (NASDAQ:ARDX): Cash Flow
Jun 2023	-14.73M	-59.20M	11.51M
Sep 2023	-21.46M	-32.69M	57.87M
Dec 2023	-8.71M	-29.56M	25.98M
Mar 2024	-35.72M	-2.57M	52.97M

Ardelyx alternative data

Social Media

🎓 Academy: How impactful can social media data be in investment decisions

Ardelyx, Inc. (NASDAQ:ARDX): Employee count
Sep 2023	133
Oct 2023	133
Nov 2023	133
Dec 2023	133
Jan 2024	133
Feb 2024	133
Mar 2024	267
Apr 2024	267
May 2024	267
Jun 2024	267
Jul 2024	267

Ardelyx
Hedge Funds Holdings Q1 2022

38.26% -2.27%

of ARDX is owned by hedge funds

83 -16

hedge funds hold ARDX stock

39.86M -2.33M

shares is hold by hedge funds

ARDX hedge funds holdings changes

Ardelyx, Inc. (NASDAQ:ARDX): Insider trades (number of shares)
Period	Buy	Sel
Jan 2024	0	30000
Feb 2024	0	79628
Mar 2024	0	86000
Apr 2024	0	39018
May 2024	0	658075
Jun 2024	0	203182
Jul 2024	0	37500
Aug 2024	0	117006
Sep 2024	0	92876
Oct 2024	0	32500
Nov 2024	215868	145863
Dec 2024	213300	25000

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Purchase	19 Dec 2024	MOTT DAVID M director director	Common Stock	213,300	$4.67	$996,538
Option	10 Dec 2024	RAAB MICHAEL director, officer..	Common Stock	25,000	$0.99	$24,750
Sale	10 Dec 2024	RAAB MICHAEL director, officer..	Common Stock	25,000	$5.27	$131,625
Option	10 Dec 2024	RAAB MICHAEL director, officer..	Stock Option (Right to Buy)	25,000	$0.99	$24,750
Sale	25 Nov 2024	RAAB MICHAEL director, officer..	Common Stock	25,000	$5.38	$134,475
Sale	20 Nov 2024	WILLIAMS LAURA A officer: Chief Medical Officer officer: Chief Medical Officer	Common Stock	7,366	$4.8	$35,320
Sale	20 Nov 2024	ROSENBAUM DAVID P. officer: Chief Development Officer officer: Chief Development Offi..	Common Stock	4,941	$4.8	$23,692
Sale	20 Nov 2024	ROSENBAUM DAVID P. officer: Chief Development Officer officer: Chief Development Offi..	Common Stock	2,243	$4.8	$10,755
Sale	20 Nov 2024	RENZ JUSTIN A officer: Chief Financial Officer officer: Chief Financial Officer	Common Stock	5,260	$4.8	$25,222
Sale	20 Nov 2024	RAAB MICHAEL director, officer..	Common Stock	31,980	$4.8	$153,344

Status	Patent	Filling date	Issue date
Grant	Grant Utility: Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders Filling date: 27 Jan 2020 Issue date: 3 May 2022	27 Jan 2020	3 May 2022
Application	Application GLYCYRRHETINIC ACID DERIVATIVES FOR USE IN TREATING HYPERKALEMIA Filling date: 6 Feb 2020 Issue date: 7 Apr 2022	6 Feb 2020	7 Apr 2022
Grant	Grant Utility: Compounds useful for treating gastrointestinal tract disorders Filling date: 9 Jan 2018 Issue date: 8 Feb 2022	9 Jan 2018	8 Feb 2022
Application	Application HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC MUTAGENIC AND FIBROTIC CONDITIONS AND DISORDERS Filling date: 18 Sep 2018 Issue date: 9 Dec 2021	18 Sep 2018	9 Dec 2021
Grant	Grant Utility: Inhibitors of NHE-mediated antiport Filling date: 9 Jan 2018 Issue date: 19 Oct 2021	9 Jan 2018	19 Oct 2021
Application	Application ISOXAZOLYL-CARBONYLOXY AZABICYCLO[3.2.1]OCTANYL COMPOUNDS AS FXR ACTIVATORS Filling date: 7 Apr 2021 Issue date: 30 Sep 2021	7 Apr 2021	30 Sep 2021
Grant	Grant Utility: Isoxazolyl-carbonyloxy azabicyclo[3.2.1]octanyl compounds as FXR activators Filling date: 23 Aug 2017 Issue date: 17 Aug 2021	23 Aug 2017	17 Aug 2021
Application	Application NHE3-BINDING COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT Filling date: 30 Dec 2020 Issue date: 24 Jun 2021	30 Dec 2020	24 Jun 2021
Application	Application GLYCYRRHETINIC ACID DERIVATIVES FOR TREATING HYPERKALEMIA Filling date: 6 Aug 2018 Issue date: 3 Jun 2021	6 Aug 2018	3 Jun 2021
Grant	Grant Utility: Substituted 4-phenyl pyridine compounds as non-systemic TGR5 agonists Filling date: 28 Jun 2019 Issue date: 6 Apr 2021	28 Jun 2019	6 Apr 2021

Ardelyx
Earnings Call Transcripts

Quarter	Transcript
Q1 2024 2 May 2024	Q1 2024 Earnings Call Transcript
Q4 2023 22 Feb 2024	Q4 2023 Earnings Call Transcript
Q3 2023 31 Oct 2023	Q3 2023 Earnings Call Transcript
Q2 2023 2 Aug 2023	Q2 2023 Earnings Call Transcript

ARDX earnings call transcripts

Ardelyx
Executives

Insider	Age	Compensation
Mr. Michael G. Raab (1965) Pres, Chief Executive Officer & Director	60	$947,660
Ms. Susan Rodriguez (1964) Chief Commercial Officer	61	$588,960
Mr. Justin A. Renz CPA, MST, M.S.T., MBA (1972) Chief Financial Officer & Chief Accounting Officer	53	$394,740

Ardelyx
Latest News

Sunday, 24 November 2024
06:36	Ardelyx Lost The Lawsuit, But The Kidney PATIENT Act Will Save It	seekingalpha.com
Wednesday, 20 November 2024
08:00	Ardelyx to Participate at the Piper Sandler 36th Annual Healthcare Conference	globenewswire.com
Thursday, 14 November 2024
09:34	Ardelyx's Medicare Setback Casts Doubt On Long-Term Viability	seekingalpha.com
Friday, 8 November 2024
12:31	Ardelyx Responds to District Court Decision Granting Motion to Dismiss	globenewswire.com
Tuesday, 5 November 2024
08:00	Ardelyx to Participate at the 2024 Jefferies London Healthcare Conference	globenewswire.com
Thursday, 31 October 2024
23:20	Ardelyx, Inc. (ARDX) Q3 2024 Earnings Call Transcript	seekingalpha.com
18:31	Compared to Estimates, Ardelyx (ARDX) Q3 Earnings: A Look at Key Metrics	zacks.com
18:20	Ardelyx (ARDX) Reports Break-Even Earnings for Q3	zacks.com
16:02	Ardelyx Reports Third Quarter 2024 Financial Results and Provides Business Update	globenewswire.com
Monday, 28 October 2024
16:05	Ardelyx Presents Results from its IBS in America 2024 Supplemental Survey at the American College of Gastroenterology's (ACG) Annual Meeting	globenewswire.com
Thursday, 24 October 2024
11:05	Earnings Preview: Ardelyx (ARDX) Q3 Earnings Expected to Decline	zacks.com
Tuesday, 22 October 2024
21:00	ARDELYX ALERT: Bragar Eagel & Squire, P.C. is Investigating Ardelyx, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm	globenewswire.com
16:05	Ardelyx Announces Launch of Gut Matters: Discoveries and Innovations, a New Podcast for the IBS-C Patient Community	globenewswire.com
Friday, 18 October 2024
10:56	Here's Why Ardelyx (ARDX) Could be Great Choice for a Bottom Fisher	zacks.com
Thursday, 17 October 2024
08:00	Ardelyx to Report Third Quarter 2024 Financial Results on October 31, 2024	globenewswire.com
Tuesday, 15 October 2024
16:30	Shareholders that lost money on Ardelyx, Inc.(ARDX) Urged to Join Class Action – Contact Levi & Korsinsky to Learn More	accesswire.com
11:15	Ardelyx, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before October 15, 2024 to Discuss Your Rights - ARDX	accesswire.com
10:45	SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Ardelyx, Inc. of Class Action Lawsuit and Upcoming Deadlines - ARDX	accesswire.com
08:00	Ardelyx to Present Additional Data Supporting First-In-Class XPHOZAH® (tenapanor) for Adults with Chronic Kidney Disease on Dialysis at the American Society of Nephrology's Kidney Week	globenewswire.com
07:15	Investors who lost money on Ardelyx, Inc.(ARDX) should contact Levi & Korsinsky about pending Class Action - ARDX	accesswire.com
07:00	FINAL ARDX DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Ardelyx, Inc. Investors to Join the Class Action Lawsuit!	accesswire.com
05:45	ARDX LAWSUIT ALERT: Levi & Korsinsky Notifies Ardelyx, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline	prnewswire.com
Monday, 14 October 2024
16:30	Shareholders of Ardelyx, Inc. Should Contact Levi & Korsinsky Before October 15, 2024 to Discuss Your Rights - ARDX	accesswire.com
13:29	Ardelyx, Inc. Class Action: Levi & Korsinsky Reminds Ardelyx Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 15, 2024 – ARDX	globenewswire.com
11:15	Shareholders that lost money on Ardelyx, Inc.(ARDX) should contact Levi & Korsinsky about pending Class Action - ARDX	accesswire.com
11:00	The Schall Law Firm Encourages Shareholder Participation In A Securities Fraud Case Against Ardelyx, Inc.	accesswire.com
10:45	Investors Who Lost Money on Ardelyx, Inc. (ARDX) Should Contact Levi & Korsinsky About Pending Class Action - ARDX	accesswire.com
10:15	ARDX Investors Have Opportunity to Lead Ardelyx, Inc.Securities Fraud Lawsuit with the Schall Law Firm	prnewswire.com
07:15	Investors who Lost Money on Ardelyx, Inc. (ARDX) Should Contact Levi & Korsinsky About Pending Class Action - ARDX	accesswire.com
07:00	FINAL REMINDER ARDX DEADLINE: Bronstein, Gewirtz & Grossman LLC Alerts Ardelyx, Inc. Investors to Participate in the Class Action Lawsuit!	accesswire.com

Ideas & Opinions

Seeking Alpha 15 Aug 2025

Ardelyx: Improved Outlook For Ibsrela And Xphozah
Seeking Alpha 24 Jul 2025

Unicycive Therapeutics: Manageable CMC Speed Bump - Pill Burden Edge Intact, Buying
Seeking Alpha 13 Jul 2024

Ardelyx: Increased Focus On Ibsrela Due To Xphozah's Uncertain Outlook
Seeking Alpha 31 Jan 2024

Ardelyx's XPHOZAH Still An Afterthought To The Pros
Seeking Alpha 10 Jan 2024

Ardelyx: FDA Approval For Xphozah Grants Further Sales Enhancement
Seeking Alpha 20 Dec 2023

Ardelyx Is Beginning To Look Highly Interesting Again
Seeking Alpha 3 Nov 2023

Akebia Therapeutics: Waiting For Round 2
Seeking Alpha 18 Oct 2023

Ardelyx: XPHOZAH Is No Niche Product
Seeking Alpha 9 Oct 2023

Rising Sun Over Ardelyx: A Tenapanor Tale (Rating Upgrade)
Seeking Alpha 31 Jul 2023

August MDA Breakout Stocks Week 31 - 2023: High-Frequency Gainers To Give You An Edge

Frequently Asked Questions (FAQ)

What's the price of Ardelyx stock today?

One share of Ardelyx stock can currently be purchased for approximately $5.84.
When is Ardelyx's next earnings date?

Unfortunately, Ardelyx's (ARDX) next earnings date is currently unknown.
Does Ardelyx pay dividends?

No, Ardelyx does not pay dividends.
How much money does Ardelyx make?

Ardelyx has a market capitalization of 1.10B and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 138.61% to 124.46M US dollars.
What is Ardelyx's stock symbol?

Ardelyx, Inc. is traded on the NASDAQ under the ticker symbol "ARDX".
What is Ardelyx's primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of Ardelyx?

Shares of Ardelyx can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are Ardelyx's key executives?
Ardelyx's management team includes the following people:
- Mr. Michael G. Raab Pres, Chief Executive Officer & Director(age: 60, pay: $947,660)
- Ms. Susan Rodriguez Chief Commercial Officer(age: 61, pay: $588,960)
- Mr. Justin A. Renz CPA, MST, M.S.T., MBA Chief Financial Officer & Chief Accounting Officer(age: 53, pay: $394,740)
How many employees does Ardelyx have?

As Jul 2024, Ardelyx employs 267 workers.
When Ardelyx went public?

Ardelyx, Inc. is publicly traded company for more then 11 years since IPO on 19 Jun 2014.
What is Ardelyx's official website?

The official website for Ardelyx is ardelyx.com.
Where are Ardelyx's headquarters?

Ardelyx is headquartered at 400 Fifth Avenue, Waltham, MA.
How can i contact Ardelyx?

Ardelyx's mailing address is 400 Fifth Avenue, Waltham, MA and company can be reached via phone at +51 07451700.

Ardelyx, Inc.

ardelyx.com

Exchange:

NASDAQ

Full time employees:

267

Industry:

Biotechnology

Sector:

Healthcare

Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase III clinical trial to control serum phosphorus in adult patients with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia. It is also developing RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease; and RDX020, an early-stage program in metabolic acidosis, a serious electrolyte disorder in patients with CKD. The company has agreements with Kyowa Kirin in Japan, Fosun Pharmaceutical Industrial Development Co. Ltd. in China, and Knight Therapeutics, Inc. in Canada for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.

+51 07451700

400 Fifth Avenue
Waltham, MA 02451

CIK: 0001437402
ISIN: US0396971071
CUSIP: 039697107